41 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
32
Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kd inhibitors.
AstraZeneca
10
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis.
University of Lille
11
Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.
Politecnico di Milano
95
Designed multiple ligands. An emerging drug discovery paradigm.
Organon Laboratories
9
Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.
University Institute of Pathology
28
Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
Novartis Institute For Biomedical Research
26
Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.
F. Hoffmann-La Roche
37
Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
Novartis Pharmaceuticals
24
Hydroxamic acids as potent inhibitors of endothelin-converting enzyme from human bronchiolar smooth muscle.
Berlex Laboratories
50
Potent and selective inhibitors of an aspartyl protease-like endothelin converting enzyme identified in rat lung.
Abbott Laboratories
7
Phosphorus-containing inhibitors of endothelin converting enzyme: effects of the electronic nature of phosphorus on inhibitor potency.
Monsanto
10
Design, synthesis and biological activity of novel non-peptidyl endothelin converting enzyme inhibitors, 1-phenyl-tetrazole-formazan analogues.
Sumitomo Pharmaceuticals
17
Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11
TBA
18
Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11
TBA
12
Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon
TBA
17
Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.
Cea
2
Non-peptidic inhibitors of neutral endopeptidase 24.11 2. Design and pharmacology of orally active phosphonate prodrugs
TBA
47
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides.
Pfizer
34
Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis.
Bayer Healthcare
21
Synthesis and biological activity of potent heterocyclic thiol-based inhibitors of endothelin-converting enzyme-1.
Novartis Institute For Biomedical Research
21
N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities.
University of Paris
16
Synthesis of triazole-Tethered pyrrolidine libraries: novel ECE inhibitors.
F. Hoffmann-La Roche
16
2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2lambda6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors.
F. Hoffmann-La Roche
5
Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
Qpex Biopharma
16
Synthesis and biological activity of novel potent endothelin-converting enzyme-1 inhibitors.
Novartis Institute For Biomedical Research
40
Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.
Roche Pharma Research and Early Development
16
Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1.
Novartis Institute For Biomedical Research
1
Synthesis of a phostone glycomimetic of the endothelin converting enzyme inhibitor phosphoramidon.
Université
17
Synthesis of novel substituted pyridines as inhibitors of endothelin converting enzyme-1 (ECE-1).
Warner-Lambert
52
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.
Shionogi
147
8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives
Idorsia Pharmaceuticals
48
1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS
Abbvie